Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. (NASDAQ: STIM) is a commercial stage medical technology and healthcare company focused on neurohealth and psychiatric disorders, and its news flow reflects this focus. The company develops and markets the NeuroStar Advanced Therapy System, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment used in office-based settings, and operates Greenbrook TMS treatment centers across the United States. News about Neuronetics often centers on clinical use of NeuroStar TMS, payer coverage decisions, and developments at its Greenbrook clinics.
Investors following STIM news can expect regular updates on quarterly financial and operating results, as the company reports revenue by geography and product category, including NeuroStar system sales, treatment sessions, and U.S. clinic revenue. Press releases also cover changes to its capital structure and credit facilities, such as amendments to its agreement with Perceptive Credit Holdings IV, LP, as well as at-the-market equity offerings and related capital-raising activities.
Company announcements frequently highlight health policy and reimbursement milestones, including expanded coverage for TMS therapy by New York State Medicaid and TRICARE West for specific patient populations with major depressive disorder. Neuronetics also reports on partnerships and agreements that expand access to NeuroStar TMS, such as an exclusive three-year collaboration with Elite DNA Behavioral Health, under which Neuronetics becomes the sole provider of TMS devices across that network and offers operational and patient-support services using the Greenbrook platform.
Additional STIM news items include participation in investor conferences, leadership and executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and publications of real-world clinical data from the NeuroStar outcomes databases. For readers tracking Neuronetics, this news page aggregates these developments so they can monitor financial performance, payer coverage trends, clinical evidence, and corporate actions related to NeuroStar TMS and Greenbrook treatment centers.
Neuronetics, Inc. (NASDAQ: STIM) has entered an exclusive five-year commercial agreement with Success TMS, which will utilize Neuronetics’ NeuroStar Advanced Therapy exclusively to treat patients with treatment-resistant major depressive disorder (MDD). Additionally, Neuronetics has made a strategic investment of $10 million to support Success TMS's growth. Success TMS aims to triple its size in the next two years, having provided over 250,000 treatments across 30 sites in six states. This partnership emphasizes the commitment to improving patient access to non-drug therapies for neurohealth disorders.
Neuronetics, a medical technology company focused on neurohealth, has announced new partnerships with mental health advocates for National Depression Education and Awareness Month. The company’s NeuroStar® Therapy leads the non-invasive treatment for depression. The campaign, featuring Dr. Melissa Shepard, aims to educate patients and physicians on this breakthrough technology. Additionally, NeuroStar is sponsoring key events to raise awareness and promote mental health research. With over four million treatments delivered, NeuroStar remains committed to transforming lives through effective non-drug therapies.
Neuronetics (NASDAQ: STIM) has partnered with Zion Healing to become the exclusive supplier of TMS equipment for Zion's mental health clinics. This agreement aims to enhance patient access to NeuroStar® Advanced Therapy, a non-invasive treatment for depression. Robert Beatty, CEO of Zion Healing, emphasized the urgent need for mental health services, while Neuronetics' President, Keith J. Sullivan, highlighted the partnership's potential to expand treatment availability. NeuroStar has delivered over 4 million treatments, demonstrating its efficacy in adult patients with major depressive disorder.
Neuronetics, Inc. (NASDAQ: STIM) announced the launch of an enhanced website aimed at improving the user experience for patients seeking information on advanced depression treatments. Market research reveals that 67% of Major Depressive Disorder patients are dissatisfied with current treatments. The new site provides essential resources, including a physician locator tool and success stories, to empower patients and healthcare providers. With rising depression rates post-COVID-19, this initiative underscores Neuronetics' commitment to addressing unmet mental health needs.
Neuronetics (NASDAQ: STIM) has appointed Megan Rosengarten to its Board of Directors, expanding the board to eight members. Rosengarten brings over two decades of experience in medical technology, currently serving as President of Surgical Robotics at Medtronic. She previously held roles at Hologic, Covidien, and Johnson & Johnson. Her expertise in product development and marketing is expected to enhance Neuronetics' growth strategy for its NeuroStar Advanced Therapy for Mental Health, which is FDA-cleared for treating major depressive disorder. The company aims to increase awareness and adoption of this innovative therapy.
Neuronetics, a medical technology company, reported a 46% revenue increase to $14.2 million for Q2 2021, driven by a 65% rise in U.S. treatment session revenue. The company highlighted 83% response and 62% remission rates from its NeuroStar Outcomes Registry. While gross margin improved to 80.6%, operating expenses rose to $18 million. A net loss of $(7.5) million was reported, slightly better than the previous year's $(7.8) million. For full-year 2021, revenue is projected between $59 million and $63 million, with Q3 expectations between $15 million and $16 million.
Neuronetics, a commercial-stage medical technology company focused on improving the quality of life for psychiatric disorder patients, announced its participation in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021. CEO Keith Sullivan and CFO Steve Furlong will present at 9:30 am ET. The presentation will be available via live audio webcast on the company’s investor relations page, with a replay accessible for 90 days. Neuronetics’ flagship product, NeuroStar, is a FDA-cleared therapy for major depressive disorder.
Neuronetics, based in Malvern, PA, announced it will release its second quarter financial and operational results on August 3, 2021, before the market opens. A conference call will follow at 8:30 a.m. ET to discuss the results. Investors can listen via a webcast on Neuronetics' investor relations site or by dialing in using a provided telephone number and confirmation code. The company specializes in medical technology aimed at improving the quality of life for patients with psychiatric disorders, notably through its FDA-cleared NeuroStar® Advanced Therapy System.
Neuronetics has launched a redesigned My NeuroStar Resource Center to enhance marketing and educational support for NeuroStar® providers. This digital hub offers over 25 customizable templates and resources to boost treatment awareness for the NeuroStar Advanced Therapy for Mental Health, a non-invasive treatment for depression. With 17.3 million Americans suffering from depression, the resource center aims to help practices effectively reach more patients. Enhancements include improved user experience and new training materials, aligning with the company’s goal to support growth in the TMS market.
Neuronetics (NASDAQ: STIM) announced its inclusion in the Russell 2000 Index effective June 28, 2021, following the annual Russell indexes reconstitution. This recognition is based on the company's market capitalization as of May 7. The Russell index membership enhances Neuronetics' visibility among investors and validates its efforts to create shareholder value through its NeuroStar Advanced Therapy System, aimed at improving mental health outcomes. Approximately $10.6 trillion in assets are benchmarked against Russell indexes, making this a significant milestone for the company.